IGC Pharma, Inc. (IGC)
(Delayed Data from AMEX)
$0.46 USD
+0.03 (6.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.45 -0.01 (-1.75%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for IGC Pharma, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 1 | 0 | 1 | 4 |
Cost Of Goods | NA | 0 | 0 | 1 | 4 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 12 | 16 | 9 | 7 |
Income After Depreciation & Amortization | 0 | -12 | -15 | -9 | -7 |
Non-Operating Income | NA | 0 | 0 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -12 | -15 | -9 | -7 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -12 | -15 | -9 | -7 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -12 | -15 | -9 | -7 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -11 | -15 | -8 | -7 |
Depreciation & Amortization (Cash Flow) | NA | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -12 | -15 | -9 | -7 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 52.58 | 49.99 | 41.96 | 39.49 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.19 | -0.21 | -0.17 |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.30 | -0.21 | -0.19 |
Fiscal Year end for IGC Pharma, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.20 | 0.29 | 0.56 | 0.17 |
Cost Of Goods | NA | 0.07 | 0.12 | 0.30 | 0.10 |
Gross Profit | NA | 0.13 | 0.17 | 0.26 | 0.06 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.13 | 2.67 | 2.40 | 4.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.00 | -2.50 | -2.14 | -4.00 |
Non-Operating Income | NA | -2.59 | 0.04 | 0.06 | -0.03 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -5.59 | -2.45 | -2.08 | -4.03 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.59 | -2.45 | -2.08 | -4.03 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.59 | -2.45 | -2.08 | -4.03 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 63.73 | 54.30 | 53.08 | 52.88 |
Diluted EPS Before Non-Recurring Items | NA | -0.09 | -0.05 | -0.04 | -0.08 |
Diluted Net EPS (GAAP) | NA | -0.09 | -0.05 | -0.04 | -0.08 |